Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial (Q40231174)

From Wikidata

Jump to navigation Jump to search

scientific article published on 20 April 2017

Language	Label	Description	Also known as
English	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial	scientific article published on 20 April 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

phase I clinical trial

0 references

phase II clinical trial

0 references

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Ignacio Melero, MD-PhD

21

object named as

Ignacio Melero

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Anthony B El-Khoueiry

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Todd S Crocenzi

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Chiun Hsu

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Tae-You Kim

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Su-Pin Choo

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Jörg Trojan

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Theodore H Welling

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Tim Meyer

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Yoon-Koo Kang

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Akhil Chopra

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Jeffrey Anderson

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Christine Dela Cruz

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Lixin Lang

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Jaclyn Neely

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Hao Tang

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Homa B Dastani

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Masatoshi Kudo

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

language of work or name

0 references

publication date

20 April 2017

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

389

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

10088

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

2492-2502

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Global cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Emerging Opportunities and Challenges in Cancer Immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Immune checkpoint blockade: a common denominator approach to cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunological landscape and immunotherapy of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Potential of immunotherapy for hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2931046-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(17)31046-2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28434648%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40231174&oldid=1889634057"